ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 531 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Gonadotropin-Releasing Hormone Antagonism in Severe Biologic Refractory Rheumatoid Arthritis

    Anita Kass1, Hans Christian Gulseth 1 and Camilla Zettel 1, 1Betanien Hospital, Skien, Norway

    Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is unclear, and additional therapeutic approaches are needed. The improvement of RA disease activity during pregnancy, and flares during the…
  • Abstract Number: 985 • 2019 ACR/ARP Annual Meeting

    Inhibition of Calcium/calmodulin-dependent Protein Kinase IV in Rheumatoid Arthritis: Dual Effect on Th17 Cell Activation and Osteoclastogenesis

    Tomohiro Koga1, Tomohito Sato 2, Yushiro Endo 1, Sosuke Tsuji 1, Ayuko Takatani 1, Toshimasa Shimizu 1, Remi Sumiyoshi 1, Takashi Igawa 1, Shin-ya Kawashiri 1, Naoki Iwamoto 1, Kunihiro Ichinose 1, Mami Tamai 1, Hideki Nakamura 1, Tomoki Origuchi 3, Nobuya Yoshida 4, Masataka Umeda 5, George Tsokos 4 and Atsushi Kawakami 6, 1Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, 2Nagasaki University, Nagasaki, Japan, 3Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, 4Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 5Beth Israel Deaconess Medical Center, Boston, MA, 6Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki

    Background/Purpose: Background: CD4 + T cells are important in the pathogenesis of rheumatoid arthritis (RA), and therapies targeting the differentiation of osteoclasts are attracting attention. Calcium/calmodulin-dependent…
  • Abstract Number: 1400 • 2019 ACR/ARP Annual Meeting

    Real Life Retention of Tofacitinib in Patients with Rheumatoid Arthritis

    Aniela Croiteru 1, Merav Lidar 2, Tatiana Reitblat3, Devy Zisman 4, Alexandra Balbir-Gurman 5, Tanya Meshiach 5, Ronit Almog 5 and Ori Elkayam 6, 1Tel Aviv medical center, Tel Aviv, Israel, 2Sheba Medical Center, Ramat Gan, Israel, 3Barzilai Medical Center, Ashkelon, Israel, 4Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel, 5Rambam Medical Center, Haifa, Israel, 6Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel

    Background/Purpose: Tofacitinib (Xeljanz) is an approved treatment for Rheumatoid Arthritis (RA) but data on its use in “real life” are limited.  We sought to analyze…
  • Abstract Number: 2002 • 2019 ACR/ARP Annual Meeting

    Presence of the MerTK Receptor on Human Synovial Tissue Macrophages Lowers Inflammatory Cytokine Production and Activation of the MerTK+CD206+ Subpopulation Limits the Inflammatory Response of Synovial Fibroblasts

    Samuel Finlay1, Stefano Alivernini 2, Aziza Elmesmari 3, Barbara Tolusso 2, Luca Petricca 2, Clara Di Mario 4, Annunziata Capacci 2, Andrew Filer 5, Gianfranco Ferraccioli 2, Iain McInnes 1, Elisa Gremese 2 and Mariola Kurowska-Stolarska 1, 1Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 3Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, 4Institute of Rheumatology - Università Cattolica del Sacro Cuore, Rome, Italy, 5Institute of Inflammation and Ageing College of Medical and Dental Sciences University of Birmingham, Birmingham, United Kingdom

    Background/Purpose: Background: A substantial proportion of Rheumatoid Arthritis patients do not respond to treatment and only a small proportion achieve sustained disease remission. We showed…
  • Abstract Number: 2380 • 2019 ACR/ARP Annual Meeting

    Improving Depression by Joint Surgery in Established Rheumatoid Arthritis; Results from Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Patient’s Reported Outcome

    Toshihisa Kojima1, Masayo Kojima 2, Hajime Ishikawa 3, Sakae Tanaka 4, Nobuhiko Haga 5, Keiichiro Nishida 6, Masao Yukioka 7, Jun Hashimoto 8, Hisaaki Miyahara 9, Yasuo Niki 10, Tomoatsu Kimura 11, Hiromi Oda 12, Shuji Asai 1, Koji Funahashi 13 and Naoki Ishiguro 1, 1Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Nagoya City University Graduate School of Medicne, Nagoya, Japan, 3Niigata Rheumatic Center, Niigata, Japan, 4University of Tokyo, Tokyo, Japan, 5The University of Tokyo Hospital, Tokyo, Japan, 6Okayama University, Graduate School of Medicine, Okayama, Japan, 7Yukioka Hospital, Osaka, Japan, 8National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan, 9National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan, 10Keio University, School of Medicine, Tokyo, Japan, 11University of Toyama, Faculty of Medicine, Toyama, Japan, 12Department of Orthopedic Surgery, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 13Kariya-Toyota General Hosptal, Kariya, Japan

    Background/Purpose: Total management including reconstructive joint surgery and rehabilitation should be needed for further improvements of physical function for long-standing RA patients. In these days,…
  • Abstract Number: 500 • 2019 ACR/ARP Annual Meeting

    The Dysregulation of NK Cells and Non-Conventional NK-T and γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis

    Klára Prajzlerová1, Olga Kryštůfková 2, Petra Hánová 3, Hana Hulejová 3, Monika Gregová 1, Nora Petrovská 1, Herman Mann 4, Karel Pavelka 4, Jiří Vencovský 4, Ladislav Senolt 4 and Mária Filková 1, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 2Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague, Czech Republic, 3Institute of Rheumatology, Prague, Czech Republic, 4Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic

    Background/Purpose: The positivity of antibodies against citrullinated proteins (ACPA) precedes the clinical manifestation and significantly increases the risk of rheumatoid arthritis (RA). EULAR characterised individuals…
  • Abstract Number: 538 • 2019 ACR/ARP Annual Meeting

    Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks

    Gerd Burmester1, Filip Van den Bosch 2, Louis Bessette 3, Alan Kivitz 4, Yihan Li 5, Alan Friedman 6, Aileen Pangan 6, Heidi Camp 5 and Joel Kremer 7, 1Charité—University Medicine Berlin, Berlin, Germany, 2Ghent University Hospital, Ghent, Belgium, 3Laval University, Quebec City, QC, Canada, 4Altoona Center for Clinical Research, Duncansville, PA, 5AbbVie Inc., North Chicago, IL, 6AbbVie Inc., North Chicago, 7Albany Medical College, Albany, NY

    Background/Purpose: Upadacitinib (UPA), an oral, JAK1-selective inhibitor showed efficacy over 12 weeks (wks) in patients (pts) with moderately to severely active rheumatoid arthritis (RA) and…
  • Abstract Number: 988 • 2019 ACR/ARP Annual Meeting

    Translational Imaging of Treatment Effects for a Novel Anti-TNF-Steroid Antibody Drug Conjugate in a Rat Model of Rheumatoid Arthritis

    Bradley Hooker1, Xiaomeng Zhang 2, Todd Cole 2, Ann Tovcimak 2, Shaughn Bryant 3, Lucy Phillips 3, David Blanchard 2, Dustin Wooten 2, Qi Guo 2, Melanie Ruzek 3, Adrian Hobson 3, Michael McPherson 3, Robert Stoffel 3, Wendy Waegell 3 and Yanping Luo 2, 1AbbVie, North Chicago, IL, 2AbbVie, North Chicago, 3AbbVie, Worcester

    Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory joint disease of autoimmune etiology.  If insufficiently treated, RA leads to joint damage and irreversible disability.  Although there…
  • Abstract Number: 1401 • 2019 ACR/ARP Annual Meeting

    Australian Rheumatoid Arthritis (RA) Biologic Treatment Pathways: An Australian Rheumatology Association Database (ARAD) Analysis

    Ashley Fletcher 1, Marissa Lassere2, Lyn March 3, Catherine Hill 4, Claire Barrett 5, Graeme Carroll 6 and Rachelle Buchbinder 1, 1Cabrini Health/Monash University, Melbourne, Australia, 2St George Hospital, University of New South Wales, Sydney, Australia, 3University of Sydney, Sydney, Australia, 4Royal Adelaide Hospital/The University of Adelaide/The Queen Elizabeth Hospital, Adelaide, Australia, 5Redcliffe Hospital, University of Queensland, Redcliffe, Australia, 6Fiona Stanley Hospital, Perth, Australia

    Background/Purpose: To describe current biologic disease-modifying antirheumatic drug (bDMARD) treatment patterns for Australian Rheumatology Association Database (ARAD) participants with Rheumatoid Arthritis (RA) including switching and…
  • Abstract Number: 2004 • 2019 ACR/ARP Annual Meeting

    Protein Profiling and Network Enrichment Analysis in Individuals Before and After the Onset of Rheumatoid Arthritis

    Mikael Brink 1, Anders Lundquist 1, Andrey Alexeyenko 2, Kristina Lejon 1 and Solbritt Rantapää-Dahlqvist1, 1Umeå University, Umeå, Sweden, 2SciLife lab, Stockholm, Sweden

    Background/Purpose: Antibodies and up-regulated cytokines and chemokines predate the onset of symptoms of rheumatoid arthritis (RA). The aims with this study was to identify pathways…
  • Abstract Number: 2381 • 2019 ACR/ARP Annual Meeting

    Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Clifton Bingham 4, Thomas Huizinga 5, Gustavo Citera 6, Kuan-Hsiang Gary Huang 7, Sean Connolly 7, Yedid Elbez 8, Karissa Lozenski 9 and Roy Fleischmann 10, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, NY, 4Johns Hopkins University, Baltimore, MD, 5Leiden University Medical Center, Leiden, Netherlands, 6Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 7Bristol-Myers Squibb, Princeton, NJ, 8Excelya, Boulogne-Billancourt, France, 9Bristol-Myers Squibb, Princeton, 10Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: The Phase IIIb Assessing Very Early Rheumatoid arthritis Treatment (AVERT)-2 trial (NCT02504268) is evaluating SC abatacept (ABA) + MTX versus ABA placebo (PBO) +…
  • Abstract Number: 504 • 2019 ACR/ARP Annual Meeting

    A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis

    Kenneth Kalunian1, Mark Genovese 2, Jacques-Eric Gottenberg 3, Beatrix Bartok 4, Alena Pechonkina 4, Ying Guo 4, Chantal Tasset 5, John Sundy 4, Kurt de Vlam 6, David Walker 7 and Tsutomu Takeuchi 8, 1Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, 2Stanford University, Stanford, CA, 3Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 4Gilead Sciences, Inc., Foster City, CA, 5Galapagos NV, Mechelen, Belgium, 6Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, 7Northumbria Healthcare, Northumbria, United Kingdom, 8Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: RA patients who have failed biologic DMARDs represent an unmet medical need. We explored the impact of baseline demographics and clinical characteristics on filgotinib…
  • Abstract Number: 539 • 2019 ACR/ARP Annual Meeting

    A Randomized Double-Blind Study Comparing Pharmacokinetics (PK) and Pharmacodynamics (PD) of ABP 798 with Rituximab in Subjects with Moderate to Severe RA

    Gerd Burmester1, Stanley Cohen 2, David Chien 3, Vincent Chow 3 and Zhiying Pan 3, 1Charité—University Medicine Berlin, Berlin, Germany, 2Metroplex Clinical Research Center, Dallas, TX, 3Amgen, Thousand Oaks, CA

    Background/Purpose: ABP 798 is being developed as a biosimilar to rituximab, a CD20-directed cytolytic antibody that is approved in the US and EU for treatment…
  • Abstract Number: 989 • 2019 ACR/ARP Annual Meeting

    Lineage Tracing of Murine Lymphatic Smooth Muscle Cells to Determine the Role of the Lymphatic System in Inflammatory Arthritis

    H. Mark Kenney1, Richard Bell 2 and Edward Schwarz 1, 1University of Rochester, Rochester, NY, 2University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Dysfunction of lymphatic vessel contraction has been implicated in inflammatory arthritis progression and arthritic flare in murine models. Previous studies have demonstrated that tumor…
  • Abstract Number: 1404 • 2019 ACR/ARP Annual Meeting

    Treatments Patterns Among Patients with Rheumatoid Arthritis Treated with a Biologic Disease-modifying Anti-rheumatic Drug: A Nation-wide Study in Korea

    Min Jung Kim1, Anna Shin 2, Seonghwan Shin 2, You-Jung Ha 3, Yun Jong Lee 4, Eun Bong Lee 5, Yeong-Wook Song 1 and Eun Ha Kang 3, 1Seoul National University Hospital, Seoul, Republic of Korea, 2Seoul National University Bundang Hospital, Seongnam, Republic of Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, 4Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, 5Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul

    Background/Purpose: Limited data are available on whether patients with rheumatoid arthritis (RA) are treated with conventional disease-modifying anti-rheumatic drugs (cDMARDs) according to the current recommendations…
  • « Previous Page
  • 1
  • …
  • 165
  • 166
  • 167
  • 168
  • 169
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology